Erratum to: Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trial

Erratum to: J Cancer Res Clin Oncol (2014) 140:211–219 DOI 10.1007/s00432-013-1568-0

Few values in Tables 1 and 3 are inadvertently published wrongly in the original publication of this article. The corrected values with revised tables are listed below.

Table 1.

Baseline characteristics of patients

Patient characteristics	Group A (N = 43)	Group B (N = 42)	P value
Demography
Age			0.754
>50 year	25	23
<50 year	18	19
Sex			1.000a
Male/female	39/4	39/3
Aetiology			0.298b
HBV/HCV/alcohol	40/2/1	40/1/1
Morphology			0.733
Multi-nodular/diffuse/massive	15/19/9	18/17/7
Maximum diameter			0.700
>5 cm	28	29
≤5 cm	15	13
α-Fetoprotein			0.593
>400 ng/mL	25	29
≤400 ng/mL	18	13
Location of tumour thrombosis			0.778b
MPV + RPVB	33	31
MPV + LPVB	7	9
MPV + RPVB + LPVB	3	2
Ascites			0.922
Yes	24	23
No	19	19
Child-Pugh class			0.756
A	17	18
B	26	24
ECOG			0.379
0/1/2	8/26/9	7/28/7

MPV main portal vein, RPVB right portal vein branches, LPVB left portal vein branches, massive tumour: maximum diameter >10 cm

^aFisher’s exact test was used

^bThe likelihood ratio test was used

Table 3.

Significant factors associated with survival time in univariate analysis

Characteristics	No. of cases	Survival time [Mean (SD)]	χ 2	P value
Child-Pugh			8.63	0.005
A	17	214.18 (98.95)
B	26	167.65 (65.55)
ECOG			15.59	0.000
0	8	292.12 (53.55)
1	26	197.27 (77.04)
2	9	110.33 (37.37)
PVTT			6.93	0.012
Response	9	260.44 (108.82)
Non-response	34	179.55 (73.58)
Intrahepatic response			25.32	0.000
CR + PR	10	293.50 (102.40)
SD + PD	33	167.39 (56.79)